Skip to main content
SpringerLink
Log in
Book cover

Geriatrische Onkologie pp 271–283Cite as

Hochmaligne Non-Hodgkin Lymphome beim alten und geriatrischen Patienten

  • Chapter
  • First Online:

  • 1622 Accesses

Part of the book series: Springer Reference Medizin ((SRM))

Zusammenfassung

Das hochmaligne Non-Hodgkin Lymphom ist eine aggressiv verlaufende Erkrankung, die überwiegend aus B-Lymphozyten hervorgeht. Grundsätzlich ist das aggressive Non-Hodgkin Lymphom eine Erkrankung, die im höheren Lebensalter auftritt. Das mediane Alter zum Zeitpunkt der Diagnosestellung beträgt ca. 65 Jahre. Therapie der Wahl ist die Systemtherapie bestehend aus dem monoklonalen Antikörper Rituximab und der Kombinationschemotherapie nach dem CHOP Protokoll. Begleitet wird die Therapie von einer anti-infektiösen Supportivtherapie. Die systemische, chemotherapeutische Behandlung erfolgt sowohl bei alten als auch sehr alten Patienten mit einem kurativen Behandlungsziel. Allerdings muss insbesondere bei sehr alten Patienten >80 Jahre die Therapie dosisreduziert nach dem R-mini CHOP verabreicht werden. Neben dem Stadium der Erkrankung wird die Prognose der Erkrankung entscheidend vom Allgemeinzustand bestimmt.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Bergenthal N, Will A, Streckmann F, Wolkewitz KD, Monsef I, Engert A, Elter T, Skoetz N (2014) Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database Syst Rev (11):CD009075

    Google Scholar 

  • Bittenbring J, Neumann F, Altmann B et al (2014) Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of DLBCL patients treated with, but not without rituximab. J Clin Oncol (im Druck). https://www.dshnhl.org/dshnhl/vitamin-d/. Zugegriffen am 15.08.2017

  • Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group, Grupo Español de Médula Ósea, German High-Grade Lymphoma Study Group, German Hodgkin’s Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

    Article  PubMed  PubMed Central  Google Scholar 

  • Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817–1826

    Article  CAS  PubMed  Google Scholar 

  • Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A (2013) Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 14(6):525–533

    Article  CAS  PubMed  Google Scholar 

  • Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S (2014) Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 19(12):1249–1257

    Article  PubMed  PubMed Central  Google Scholar 

  • Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, Bittenbring J, Hänel M, Wilhelm S, Schubert J, Schmitz N, Löffler M, Rübe C, Pfreundschuh M (2014) Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32(11):1112–1118

    Article  PubMed  Google Scholar 

  • Howlander N et al. SEER Cancer Statistics Review, 1975–2012. National Cancer Institute, Bethesda

    Google Scholar 

  • Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31(22):2765–2772

    Article  CAS  PubMed  Google Scholar 

  • Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Houterman S, Verheij KD, Coebergh JW (2005) A population-based study of severity of comorbidity among patients with non-Hodgkin’s lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 129(5):597–606

    Article  PubMed  Google Scholar 

  • Kobayashi Y, Miura K, Hojo A, Hatta Y, Tanaka T, Kurita D, Iriyama N, Kobayashi S, Takeuchi J (2011) Charlson Comorbidity Index is an independent prognostic factor among elderly patients with diffuse large B-cell lymphoma. J Cancer Res Clin Oncol 137(7):1079–1084

    Article  PubMed  Google Scholar 

  • Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 96(12):1888–1890

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, Spina M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Bottelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M, Fondazione Italiana Linfomi (2014) Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma 55(1):38–43

    Article  PubMed  Google Scholar 

  • Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C (2014) Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol 25(9):1800–1806

    Article  CAS  PubMed  Google Scholar 

  • Naito Y, Sasaki H, Takamatsu Y, Kiyomi F, Tamura K (2016) Retrospective analysis of treatment outcomes and geriatric assessment in elderly malignant lymphoma patients. J Clin Exp Hematop 56(1):43–49

    Article  PubMed  Google Scholar 

  • Onkopedia Leitlinien (2014) https://www.onkopedia.com/de/onkopedia/guidelines/diffuses-grosszelliges-b-zell-lymphom/@@view/html/index.html. Zugegriffen am 15.08.2017

  • Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC (2016) A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. https://doi.org/10.1111/bjh.14232. [Epub vor Druck]

    Google Scholar 

  • Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, Groupe d’Etude des Lymphomes de l’Adulte (GELA) Investigators (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460–468

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M (2016) Current therapeutic strategies for diffuse large B cell lymphoma. Internist (Berl) 57(3):214–221

    Article  CAS  Google Scholar 

  • Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105–116

    Article  CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N (2014) Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. J Clin Oncol 32(36):4127–4133

    Article  CAS  PubMed  Google Scholar 

  • Schans SA van de, Wymenga AN, van Spronsen DJ, Schouten HC, Coebergh JW, Janssen-Heijnen ML (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23(5):1280–1286

    Google Scholar 

  • Siegel AB, Lachs M, Coleman M, Leonard JP (2006) Lymphoma in elderly patients: novel functional assessment techniques provide better discrimination among patients than traditional performance status measures. Clin Lymphoma Myeloma 7(1):65–69

    Article  PubMed  Google Scholar 

  • Swerdlow SH et al (Hrsg) (2008) WHO classification of tumours of hematopoetic and lymphoid tissues, 4. Aufl. IARC, Lyon

    Google Scholar 

  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) Predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

    Article  Google Scholar 

  • Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M, Guidelines Committee ESMO (2015) Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116–v125

    Article  PubMed  Google Scholar 

  • Tucci A, Martelli M, Rigacci L, Riccomagno P, Cabras MG, Salvi F, Stelitano C, Fabbri A, Storti S, Fogazzi S, Mancuso S, Brugiatelli M, Fama A, Paesano P, Puccini B, Bottelli C, Dalceggio D, Bertagna F, Rossi G, Spina M, Italian Lymphoma Foundation (FIL) (2015) Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 56(4):921–926

    Article  CAS  PubMed  Google Scholar 

  • Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M, German High-Grade Non-Hodgkin Lymphoma Study Group (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22(8):1872–1877. https://doi.org/10.1111/bjh.14232. [Epub vor Druck]

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik 2 – Hämatologie, Onkologie, Immunologie, Palliativmedizin, St.-Vincentius-Kliniken Karlsruhe, Südendstr. 32, 76137, Karlsruhe, Deutschland

    Christian Meyer zum Büschenfelde

Authors
  1. Christian Meyer zum Büschenfelde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Meyer zum Büschenfelde .

Editor information

Editors and Affiliations

  1. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Matthias Ebert

  2. II. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

    Nicolai Härtel

  3. Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany

    Ulrich Wedding

Section Editor information

  1. Abteilung für Palliativmedizin, Universitätsklinikum Jena, Klinik für Innere Medizin II, Erlanger Allee 101, 07747, Jena, Deutschland

    Ulrich Wedding

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Meyer zum Büschenfelde, C. (2018). Hochmaligne Non-Hodgkin Lymphome beim alten und geriatrischen Patienten. In: Ebert, M., Härtel, N., Wedding, U. (eds) Geriatrische Onkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48727-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48727-3_21

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48726-6

  • Online ISBN: 978-3-662-48727-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation